Home » Health Care

Drug Discovery and Development

Capital Conundrum

The biotech industry has shrunk dramatically in recent years based primarily on the continued tight capital markets and increased aversion to risk on the part of investors.

Rachel King, CEO of GlycoMimetics and a BIO Board member

GlycoMimetics’ Rachel King discusses the prevalence of sickle cell disease and urgency to find treatments.

New Diabetes Forum at the 2011 BIO International Convention

The number of Americans diagnosed with diabetes — the seventh leading cause of death in the U.S. — has risen by epidemic proportions. In addition, the disease is estimated to affect 435 million people worldwide by 2030. BIO and the Juvenile Diabetes Research Foundation will feature a two-day diabetes forum for the first time at the 2011 BIO International Convention in Washington, DC. The sessions will showcase the latest research in novel therapies, vaccines, and biomarkers.

The Role of Intellectual Property in Global Health

BIO is committed to increased access to biologic medicines for patients throughout the world. 

Policies Necessary for Supporting Small Biotech Businesses

Emerging biotech companies with promising scientific innovation need a policy environment that will enable them to continue critical research and development of medical advancements and breakthroughs.

New Report Shows Monoclonal Antibody Development Times Are Lengthening

A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant.

A Conversation with the Michael J. Fox Foundation for Parkinson's Research

April is Parkinson's Awareness Month so it seemed like a good opportunity to learn more about the Michael J. Fox Foundation for Parkinson's Research.

A Conversation with the Michael J. Fox Foundation for Parkinson's Research

April is Parkinson's Awareness Month so it seemed like a good opportunity to learn more about the Michael J. Fox Foundation for Parkinson's Research.

The Cost of Losing Innovation

Current rules resulting from a 2003 Office of Hearings and Appeals decision have inhibited and interfered with the growth and survival of small private biotechnology companies and the development of promising technologies and products

On a Roll: Governor Seeks Continued Investment in BioMaryland 2020

The Maryland initiative’s 10-year plan helps build biotech access to funding

John Sterling, editor-in-chief of Genetic Engineering and Biotechnology News (GEN)

BIOtechNOW talks to GEN's John Sterling regarding the upcoming BIO International Convention.

Top Ten "Must Attend" Breakout Sessions at the 2011 BIO International Convention

GEN's Editor-in-Chief John Sterling outlines his picks for the top ten "must attend" breakout sessions at the 2011 BIO International Convention.

Countdown to Partnering With John Carroll from Fierce Biotech

John Carroll discusses the upcoming BIO International Convention.

Countdown to Partnering - John Carroll, Editor of Fierce Biotech

 John Carroll, editor of Fierce Biotech, shares what he won't miss at the 2011 BIO International Convention.

Japan’s Crippled Nuclear Plant Demonstrates Need for New Radiation Treatments

As Japan works to stabilize the crippled nuclear power plant in Fukushima, people are stocking up on potassium iodide tablets – one of the only drugs available to block the body's absorption of some radioactive materials.

Letters, Testimony & Comments

Recombinant DNA: BIO Comments on WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology
April 19 2013
  The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the “WHO Guidelines on the Quality...
Immunogenicity: BIO Comments on Draft Guidance on Immunogenicity Assessment for Therapeutic Protein Products
April 12 2013
Dear Sir/Madam: The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to...
eSource: BIO Comments on FDA Draft Guidance on Electronic Source Data in Clinical Investigations
March 26 2013
  Re: Docket No. FDA–2010-D-0643:  Draft Guidance for Industry on Electronic Source Data in Clinical Investigations;...
Enrichment Strategies: BIO Submits Comments on FDA Draft Guidance on Enrichment Strategies for Clinical Trials
March 18 2013
  Dear Sir/Madam:   The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the...
eCTD: BIO Submits Comments on Providing Regulatory Submissions in Electronic Format
March 4 2013
  The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the opportunity to...
More Letters, Testimony & Comments →

Press Releases

IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 Fields 1 Goal Campaign
July 23 2012
Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping...
BIO Supports Permanent Reauthorization of Programs to Encourage Development of Lifesaving Medications for Children
March 28 2012
Washington, D.C. (March 28, 2012) – BIO President and CEO Jim Greenwood issued the following statement in...
BIO Statement on New Bill to Extend Therapeutic Discovery Project Tax Credit
May 25 2011
WASHINGTON, D.C. (Wednesday, May 25, 2011) - Biotechnology Industry Organization (BIO) President and CEO Jim...
Representative Upton Honored as BIO Legislator of the Year
May 4 2011
WASHINGTON, D.C. (Tuesday, May 04, 2011) - The Biotechnology Industry Organization (BIO) announced today its...
Senator Casey Honored as BIO Legislator of the Year
May 4 2011
Pennsylvania Bio President Christopher Molineaux and BIO President and CEO Jim Greenwood present Senator...
More Press Releases →